Structure-Based Drug Design Approaches for Predicting Binding Affinities of Hiv1 Protease Inhibitors

1998 ◽  
Vol 14 (1) ◽  
pp. 1-14 ◽  
Author(s):  
M. Rami Reddy ◽  
Mark D. Erion
2020 ◽  
Vol 0 (0) ◽  
Author(s):  
Zbigniew Dutkiewicz

AbstractDrug design is an expensive and time-consuming process. Any method that allows reducing the time the costs of the drug development project can have great practical value for the pharmaceutical industry. In structure-based drug design, affinity prediction methods are of great importance. The majority of methods used to predict binding free energy in protein-ligand complexes use molecular mechanics methods. However, many limitations of these methods in describing interactions exist. An attempt to go beyond these limits is the application of quantum-mechanical description for all or only part of the analyzed system. However, the extensive use of quantum mechanical (QM) approaches in drug discovery is still a demanding challenge. This chapter briefly reviews selected methods used to calculate protein-ligand binding affinity applied in virtual screening (VS), rescoring of docked poses, and lead optimization stage, including QM methods based on molecular simulations.


ChemInform ◽  
2010 ◽  
Vol 26 (34) ◽  
pp. no-no
Author(s):  
V. J. KALISH ◽  
J. H. TATLOCK ◽  
J. F. II DAVIES ◽  
S. W. KALDOR ◽  
B. A. DRESSMAN ◽  
...  

2014 ◽  
Vol 20 (20) ◽  
pp. 3323-3337 ◽  
Author(s):  
M. Reddy ◽  
C. Reddy ◽  
R. Rathore ◽  
Mark Erion ◽  
P. Aparoy ◽  
...  

Author(s):  
Anoop Narayanan ◽  
Shay A. Toner ◽  
Joyce Jose

SARS-CoV-2, the coronavirus responsible for the current COVID-19 pandemic, encodes two proteases, 3CLpro and PLpro, two of the main antiviral research targets. Here we provide an overview of the structures and functions of 3CLpro and PLpro and examine strategies of structure-based drug designing and drug repurposing against these proteases. Rational structure-based drug design enables the generation of potent and target-specific antivirals. Drug repurposing offers an attractive prospect with an accelerated turnaround. Thus far, several protease inhibitors have been identified, and some candidates are undergoing trials that may well prove to be effective antivirals against SARS-CoV-2.


2021 ◽  
Author(s):  
Himanshu Goel ◽  
Anthony Hazel ◽  
Vincent D. Ustach ◽  
Sunhwan Jo ◽  
Wenbo Yu ◽  
...  

Predicting relative protein-ligand binding affinities is a central pillar of lead optimization efforts in structure-based drug design. The Site Identification by Ligand Competitive Saturation (SILCS) methodology is based on functional...


2020 ◽  
Vol 11 (4) ◽  
pp. 1140-1152 ◽  
Author(s):  
Vytautas Gapsys ◽  
Laura Pérez-Benito ◽  
Matteo Aldeghi ◽  
Daniel Seeliger ◽  
Herman van Vlijmen ◽  
...  

Relative ligand binding affinity calculations based on molecular dynamics (MD) simulations and non-physical (alchemical) thermodynamic cycles have shown great promise for structure-based drug design.


Sign in / Sign up

Export Citation Format

Share Document